AbbVie to Acquire Allergan

June 25, 2019

Applied Clinical Trials

AbbVie Inc. and Allergan plc have announced that they have entered into a definitive transaction agreement under which AbbVie will acquire Allergan for approximately $63 billion. The combined company will consist of several franchises with focus across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care, and virology.

Learn all about the acquisition, right here.

Related Content: